MALDI‐TOF MS‐based drug susceptibility testing of pathogens: The example of Candida albicans and fluconazole

MALDI‐TOF MS can be used for the identification of microorganism species. We have extended its application to a novel assay of Candida albicans susceptibility to fluconazole, based on monitoring modifications of the proteome of yeast cells grown in the presence of varying drug concentrations. The method was accurate, and reliable, and showed full agreement with the Clinical Laboratory Standards Institute's reference method. This proof‐of‐concept demonstration highlights the potential for this approach to test other pathogens.

[1]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Arikan.  Current status of antifungal susceptibility testing methods. , 2007, Medical mycology.

[3]  R. Cole,et al.  MALDI-TOF mass signatures for differentiation of yeast species, strain grouping and monitoring of morphogenesis markers , 2008, Analytical and bioanalytical chemistry.

[4]  D. Denning,et al.  Statistical Analyses of Correlation between Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2) , 2006, Journal of Clinical Microbiology.

[5]  P. Berche,et al.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Nonfermenting Gram-Negative Bacilli Isolated from Cystic Fibrosis Patients , 2008, Journal of Clinical Microbiology.

[6]  S. Redding,et al.  Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method , 1998, Journal of Clinical Microbiology.

[7]  D. Diogo,et al.  Molecular Phylogenetics of Candida albicans , 2007, Eukaryotic Cell.

[8]  J. Cleary,et al.  Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States , 2003, Antimicrobial Agents and Chemotherapy.

[9]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Pfaller,et al.  Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing , 2006, Clinical Microbiology Reviews.

[11]  C. M. Belli,et al.  Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida Species , 2002, Journal of Clinical Microbiology.

[12]  C. Lass‐Flörl,et al.  Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[13]  M. Ghannoum,et al.  Antifungal Susceptibility Testing: Practical Aspects and Current Challenges , 2001, Clinical Microbiology Reviews.

[14]  J. Guarro,et al.  Use of mass spectrometry to identify clinical Fusarium isolates. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  D. Diogo,et al.  Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates , 2007, Eukaryotic Cell.

[16]  M. Pfaller,et al.  International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole , 2005, Journal of Clinical Microbiology.

[17]  S. N. Davey,et al.  The rapid identification of intact microorganisms using mass spectrometry , 1996, Nature Biotechnology.